Insider Selling: Sionna Therapeutics (NASDAQ:SION) Director Sells 59,767 Shares of Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Peter Thompson sold 59,767 shares of Sionna Therapeutics stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $44.58, for a total transaction of $2,664,412.86. Following the completion of the transaction, the director owned 2,856,461 shares of the company’s stock, valued at $127,341,031.38. This trade represents a 2.05% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Sionna Therapeutics Stock Up 3.9%

NASDAQ:SION traded up $1.72 during mid-day trading on Monday, reaching $45.95. 670,726 shares of the company were exchanged, compared to its average volume of 474,065. The company has a fifty day moving average of $38.55 and a 200 day moving average of $39.36. Sionna Therapeutics, Inc. has a 12 month low of $11.77 and a 12 month high of $48.45.

Sionna Therapeutics (NASDAQ:SION) last announced its quarterly earnings data on Monday, March 2nd. The company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.61) by $0.15. As a group, research analysts forecast that Sionna Therapeutics, Inc. will post -2.32 EPS for the current fiscal year.

Hedge Funds Weigh In On Sionna Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Russell Investments Group Ltd. acquired a new position in Sionna Therapeutics in the third quarter valued at $30,000. BNP Paribas Financial Markets bought a new position in Sionna Therapeutics in the second quarter worth approximately $31,000. GF Fund Management CO. LTD. acquired a new stake in Sionna Therapeutics in the 4th quarter valued at $36,000. Balyasny Asset Management L.P. acquired a new position in shares of Sionna Therapeutics during the fourth quarter valued at about $58,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in Sionna Therapeutics during the 4th quarter worth approximately $89,000.

Analyst Ratings Changes

A number of research firms recently weighed in on SION. Guggenheim raised their target price on shares of Sionna Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. Citizens Jmp assumed coverage on Sionna Therapeutics in a report on Tuesday, February 24th. They set a “market outperform” rating and a $63.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Sionna Therapeutics in a report on Friday. Citigroup assumed coverage on shares of Sionna Therapeutics in a research report on Tuesday, February 24th. They issued an “outperform” rating for the company. Finally, Wedbush began coverage on Sionna Therapeutics in a research report on Tuesday, May 5th. They set an “outperform” rating and a $53.00 price target on the stock. Three investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Sionna Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $53.00.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.